Antares Pharma Stock Company Profile

Description

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It also offers Elestrin gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; and Gelnique, an oxybutynin gel product for the treatment of overactive bladder. In addition, the company is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes; VIBEX QuickShot (QS) auto injectors for reducing risk of preterm birth; VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency; and Vibex QS M for the treatment of CNS indication. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals Inc. and Ferring B.V.; JCR Pharmaceuticals Co., Ltd.; Teva Pharmaceutical Industries, Ltd.; Actavis plc; Meda Pharmaceuticals, Inc.; and AMAG Pharmaceuticals, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.